ELOXX PHARMACEUTICALS INC (ELOX)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

480 ARSENAL WAY WATERTOWN, MA 02472

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ.

Data as of 2021-07-19 08:37:15 -0400
Market Cap66.042 Million Shares Outstanding47.856 Million Avg 30-day Volume1.629 Million
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.04 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.8278 52-week High/Low6.77 / 1.34 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9.2103
Data provided by IEX Cloud
View SEC Filings from ELOX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ELOX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ELOX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BELLOFF NEIL S. COO, GENERAL COUNSEL &CORP SEC

100,345 2021-05-25 7

RUBIN STEVEN D

20,000 2021-05-19 1

VEINRIB GADI

20,000 2021-05-19 1

AVNUR ZAFRIRA

20,000 2021-05-19 1

KARIV TOMER

20,000 2021-05-19 2

NUSSBAUM RAN

20,000 2021-05-19 2

SEEHRA JASBIR

20,000 2021-05-19 1

WALTS ALAN EDMUND

3,334 2021-05-19 3

PAREKH RAJESH B

3,334 2021-05-19 4

AGGARWAL SUMIT PRESIDENT AND CEO

992,409 2021-05-18 3

MODUR VIJAY HEAD OF R&D

496,204 2021-05-18 3

PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

PONTIFAX (CHINA) IV L.P.

PONTIFAX (CAYMAN) IV L.P.

PONTIFAX (ISRAEL) IV, L.P.

PONTIFAX IV GP L.P.

  • 10% Owner
8,077,410 2021-05-13 1

GEFFKEN DANIEL E. CHIEF FINANCIAL OFFICER

100,000 2021-04-20 2

RAKERS GARY D. CONTROLLER, PFO/PAO, TREASURER

0 2021-03-24 1

WILLIAMS GREGORY C. CHIEF EXECUTIVE OFFICER

194,629 2021-02-25 5

MACDONALD STEPHEN G. VP FINANCE & ACCTG, TREASURER

0 2021-02-12 1

NOIMAN SILVIA

0 2020-05-20 0

KLEIJWEGT MARTIJN

0 2020-05-20 0

PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

PONTIFAX IV GP L.P.

PONTIFAX (CAYMAN) IV L.P.

PONTIFAX (CHINA) IV L.P.

PONTIFAX (ISRAEL) IV, L.P.

PONTIFAX MANAGEMENT III G.P. (2011) LTD.

PONTIFAX MANAGEMENT FUND III L.P.

PONTIFAX (CAYMAN) III, L.P.

PONTIFAX (ISRAEL) III, L.P.

  • 10% Owner
0 2020-05-20 0

WEAVER GREGORY L

  • FORMER CHIEF FINANCIAL OFFICER
No longer subject to file 2020-03-15 0

WARD ROBERT

  • FORMER CHAIRMAN AND CEO
No longer subject to file 2020-02-29 0

SNOW DAVID P.

  • FORMER CHIEF BUSINESS OFFICER
No longer subject to file 2020-02-29 0

PONTIFAX MANAGEMENT III G.P. (2011) LTD.

PONTIFAX MANAGEMENT FUND III L.P.

PONTIFAX (CAYMAN) III, L.P.

PONTIFAX (ISRAEL) III, L.P.

  • 10% Owner
0 2018-06-15 0

HUERTAS PEDRO CHIEF MEDICAL OFFICER

  • Officer
137,725 2018-05-16 0

SHABTAI GILAD

  • 10% Owner
3,351,770 2018-04-30 0

RECTOR DAVID

  • SEE REMARKS
No longer subject to file 2017-12-19 0

BRACA JOHN N

  • SEE REMARKS
No longer subject to file 2017-12-19 0

FROST PHILLIP MD ET AL

  • SEE REMARKS
No longer subject to file 2017-12-19 0

OPKO HEALTH, INC.

  • 10% Owner
No longer subject to file 2017-12-19 0

HEFT ROBERT

  • Director
0 2017-12-19 0

WAKSAL HARLAN

  • Director
0 2015-11-19 0

FROST PHILLIP MD ET AL

FROST GAMMA INVESTMENTS TRUST

  • Director
  • 10% Owner
1,598,170 2015-09-29 0

FORBES CHRISTOPHER

  • Director
0 2014-11-18 0

BROOKS JOEL CHIEF FINANCIAL OFFICER

  • Officer
0 2014-11-18 0

DONDERO RICHARD S VP - PRECLINICAL RESEARCH

  • Officer
0 2014-11-18 0

THOMPSON JOHN PHD SCIENTIFIC FOUNDER

  • Officer
0 2014-11-18 0

BROWNE LESLIE J PRESIDENT

  • Officer
0 2014-11-18 0

SMIDER VAUGHN CHIEF SCIENTIFIC OFFICER

  • Officer
  • Director
  • 10% Owner
0 2014-11-18 0

RIOS MIGUEL DE LOS VP - RESEARCH

  • Officer
0 2014-11-18 0

GRAZIANO JAMES JOSEPH CHIEF TECHNOLOGY OFFICER

  • Officer
0 2014-11-18 0

MARTELL RON CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2014-11-18 0

QUICK THOMAS C

  • Director
No longer subject to file 2014-05-16 0

STALDER RUEDI

  • Director
No longer subject to file 2014-05-16 0

VAN HULST JACK

  • Director
No longer subject to file 2014-05-16 0

ISABELLE WARREN JOHN

  • Director
No longer subject to file 2014-05-16 0

KLAVER PAUL EDWARD

  • 10% Owner
17,293,054 2012-03-15 0

GALTON BRUCE C

  • FORMER PRESIDENT & CEO
98,450 2009-11-30 0

FEDYSZYN SASCHA P VP - CORPORATE DEV.

  • Officer
153,460 2009-11-19 0

PARTLET HOLDINGS LTD

  • 10% Owner
2,111,111 2009-11-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 22:15:03 UTC -4.4274 4.5074 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 21:45:03 UTC -4.4274 4.5074 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 21:15:03 UTC -4.4274 4.5074 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 20:45:03 UTC -4.3731 4.4531 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 20:15:05 UTC -4.3731 4.4531 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 19:45:03 UTC -4.3731 4.4531 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 19:15:03 UTC -4.3731 4.4531 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 18:45:03 UTC -3.9381 4.0181 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 18:15:03 UTC -3.9381 4.0181 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 17:45:03 UTC -3.9381 4.0181 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 17:15:02 UTC -3.9381 4.0181 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 16:45:02 UTC -4.4882 4.5682 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 16:15:03 UTC -4.4882 4.5682 900000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 15:45:02 UTC -4.4882 4.5682 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 15:15:03 UTC -4.4882 4.5682 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 14:45:03 UTC -4.9093 4.9893 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 14:15:03 UTC -4.9093 4.9893 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 13:45:03 UTC -4.9093 4.9893 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 13:15:03 UTC -4.9093 4.9893 850000
ELOXX PHARMACEUTICALS INC ELOX 2021-07-23 12:45:03 UTC -4.9093 4.9893 850000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments